Reference-grade research compound
Cagrilintide 5mg+Semaglutide 5mg
Co-formulated reference mixture of cagrilintide (long-acting amylin analog peptide) and semaglutide (acylated GLP-1 receptor agonist peptide)
Schematic — no PDB structure deposited
- Scientific name
- Co-formulated reference mixture of cagrilintide (long-acting amylin analog peptide) and semaglutide (acylated GLP-1 receptor agonist peptide)
- Sequence
- —
- Length
- 0-mer
- Molecular formula
- Multi-peptide blend
- Molecular weight
- 0.00 g/mol
- Form
- lyophilized
- Vial size
- (5mg+5mg)
- Storage
- Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
- Batch HPLC purity
- 99.5%
Description
Two-component reference mixture combining the amylin-analog peptide cagrilintide and the acylated GLP-1 receptor agonist peptide semaglutide. Used in vitro as a combined reference preparation in amylin and GLP-1 receptor signaling assays and metabolic cell-line model systems. Supplied as a lyophilized acetate salt.
Current batch
RR-CAGRILINTIDE5MGSEMAGLUTIDE5MG-260415-B
Manufactured Apr 15, 2026
Tested Apr 21, 2026
Storage and stability
Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
Peer-reviewed references
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
EBioMedicine · 2025
PMID 40609154PubMedDiscovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
J Med Chem · 2015
PMID 26308095PubMedEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet · 2023
PMID 37364590PubMed
Titles and journals pulled from PubMed and cached for 7 days. Links open in a new tab.